XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Series D Convertible Preferred Stock
Series E Convertible Preferred Stock
Preferred Stock
Preferred Stock
Series D Convertible Preferred Stock
Preferred Stock
Series E Convertible Preferred Stock
Common Stock
Common Stock
Series D Convertible Preferred Stock
Common Stock
Series E Convertible Preferred Stock
Additional Paid-In Capital
Additional Paid-In Capital
Series D Convertible Preferred Stock
Additional Paid-In Capital
Series E Convertible Preferred Stock
Service Receivable
Accumulated other comprehensive loss
Accumulated Deficit
Accumulated Deficit
Series D Convertible Preferred Stock
Accumulated Deficit
Series E Convertible Preferred Stock
Balance (in shares) at Dec. 31, 2019       61     8,594                    
Balance at Dec. 31, 2019 $ 7,312     $ 0     $ 8     $ 217,173     $ (972) $ 0 $ (208,897)    
Increase (Decrease) in Stockholders' Equity                                  
Sale of stock, shares issued (in shares) [1]       866     12,964                    
Net proceeds [1] 112,300     $ 1     $ 1     112,298              
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount (in shares)       155     603                    
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount (8)                 2,292     (2,300)        
Stock-based compensation 1,765                 1,765              
Issuance of common stock upon exercise of warrants (in shares)             12,138                    
Issuance of common stock upon exercise of warrants 24,871           $ 1     24,870              
Issuance of common stock upon vesting of restricted stock awards (in shares)             11                    
Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance   $ 0 $ 0               $ 602 $ 2,665       $ (602) $ (2,665)
Issuance of common stock upon conversion of Convertible Preferred Stock (in shares)         (155) (211)   1,547 864                
Preferred stock dividend payable on Series A Convertible Preferred Stock (24)                           (24)    
Release of clinical trial funding commitment 1,101                       1,101        
Common Stock par value adjustment 0           $ (6)     6              
Issuance of common stock upon exercise of stock options (in shares)             60                    
Issuance of common stock upon exercise of stock options 148                 148              
Net loss (19,307)                           (19,307)    
Unrealized loss on securities available-for-sale 0                                
Balance (in shares) at Dec. 31, 2020       716     36,781                    
Balance at Dec. 31, 2020 128,158     $ 1     $ 4     361,819     (2,171) 0 (231,495)    
Increase (Decrease) in Stockholders' Equity                                  
Sale of stock, shares issued (in shares) [2]             4,412                    
Net proceeds [2] 34,187                 34,187              
Stock-based compensation 3,234                 3,234              
Issuance of common stock upon exercise of warrants (in shares)             771                    
Issuance of common stock upon exercise of warrants 1,263                 1,263              
Preferred stock dividend payable on Series A Convertible Preferred Stock (24)                           (24)    
Release of clinical trial funding commitment 2,032                       2,032        
Net loss (28,291)                           (28,291)    
Unrealized loss on securities available-for-sale (142)                         (142)      
Balance (in shares) at Dec. 31, 2021       716     41,964                    
Balance at Dec. 31, 2021 $ 140,417     $ 1     $ 4     $ 400,503     $ (139) $ (142) $ (259,810)    
[1] Net of expenses of $7.5 million, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $0.4 million.
[2] Net of expenses of $0.8 million.